Rachael Natrajan
Overview
Explore the profile of Rachael Natrajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
6149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stewart J, Krastev D, Brough R, Zatreanu D, Song F, Baxter J, et al.
Oncogene
. 2025 Feb;
44(9):618-629.
PMID: 39939726
Identification of ARID1A/ATR synthetic lethality led to ATR inhibitor phase II trials in ovarian clear cell carcinoma (OCCC), a cancer of unmet need. Using multiple CRISPR-Cas9 mutagenesis and interference screens,...
2.
Alexander J, Schipper K, Nash S, Brough R, Kemp H, Iacovacci J, et al.
Br J Cancer
. 2024 Apr;
130(11):1828-1840.
PMID: 38600325
Background: Invasive Lobular Carcinoma (ILC) is a morphologically distinct breast cancer subtype that represents up to 15% of all breast cancers. Compared to Invasive Breast Carcinoma of No Special Type...
3.
Inayatullah M, Mahesh A, Turnbull A, Dixon J, Natrajan R, Tiwari V
EMBO Mol Med
. 2024 Mar;
16(4):823-853.
PMID: 38480932
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by extensive intratumoral heterogeneity, high metastasis, and chemoresistance, leading to poor clinical outcomes. Despite progress, the mechanistic basis...
4.
Mansur M, deSouza N, Natrajan R, Abegglen L, Schiffman J, Greaves M
Nat Ecol Evol
. 2023 Aug;
7(11):1761-1770.
PMID: 37620552
The emergence of drug-resistant cells, most of which have a mutated TP53 gene, prevents curative treatment in most advanced and common metastatic cancers of adults. Yet, a few, rarer malignancies,...
5.
Thakur S, Haider S, Natrajan R
J Pathol
. 2023 Aug;
260(5):621-636.
PMID: 37587096
Tumour heterogeneity is pervasive amongst many cancers and leads to disease progression, and therapy resistance. In this review, using breast cancer as an exemplar, we focus on the recent advances...
6.
Bland P, Saville H, Wai P, Curnow L, Muirhead G, Nieminuszczy J, et al.
Nat Genet
. 2023 Jul;
55(8):1311-1323.
PMID: 37524790
SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1...
7.
Khalique S, Nash S, Natrajan R
J Pathol
. 2022 Jun;
258(1):1-3.
PMID: 35647895
The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to...
8.
Gomez-Cuadrado L, Bullock E, Mabruk Z, Zhao H, Souleimanova M, Noer P, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205651
Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer, and it exhibits a number of clinico-pathological characteristics distinct from the more common invasive ductal carcinoma...
9.
Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer
Alexander J, Mariani O, Meaudre C, Fuhrmann L, Xiao H, Naidoo K, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053458
Mutations and loss of E-cadherin protein expression define the vast majority of invasive lobular carcinomas. In a subset of these cases, the heterogeneous expression of E-cadherin is observed either as...
10.
Mavrommati I, Johnson F, Echeverria G, Natrajan R
NPJ Breast Cancer
. 2021 Dec;
7(1):155.
PMID: 34934048
Subclonal heterogeneity and evolution are characteristics of breast cancer that play a fundamental role in tumour development, progression and resistance to current therapies. In this review, we focus on the...